Biogen's Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress
LEQEMBI IQLIK® Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
LEQEMBI IQLIK® Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease
FDA Approves LEQEMBI IQLIK® Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® 2026
Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
Metalsource Mining Launches Major Step Out Program With 1.1 km Northern Target to Test Broader Scale of Silver Hill
Skyharbour Commences Drilling at the Getty East Uranium Joint Venture with Partner Denison Mines at the Russell Lake Project Area
Transition Metals Extends Geochemical Footprint of Haultain Gold System and Identifies New Large-Scale Exploration Targets at Gowganda Project, Ontario
SAGA Metals Drills 495.6 m at 37.86% Fe2O3, 5.51% TiO2, 0.273% V2O5 Including 68.2 m at 52.95% Fe2O3, 8.57% TiO2, 0.381% V2O5 at Radar Critical Minerals Project in Labrador
RETRANSMISSION: QIMC Announces Thermogenic Wet-Gas Signature in 86% of Soil-Gas Samples at New Salem-Apple River, Nova Scotia, Next to Its 30% Clean Hydrogen Discovery
